{"id":20045,"date":"2023-09-13T07:36:35","date_gmt":"2023-09-13T07:36:35","guid":{"rendered":"https:\/\/clinlabint.com\/?p=20045"},"modified":"2023-09-13T07:36:35","modified_gmt":"2023-09-13T07:36:35","slug":"transcure-bioservices-expands-reach-into-apac-with-preclina-partnership","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/transcure-bioservices-expands-reach-into-apac-with-preclina-partnership\/","title":{"rendered":"TransCure bioServices expands reach into APAC with Preclina partnership"},"content":{"rendered":"
\n

\r\n\"Forum<\/a>\r\n<\/div><\/p>\n<\/div><\/section><\/div>

\r\n\r\n\"\"<\/a>\r\n<\/div><\/p>\n<\/div><\/section>
\n

TransCure bioServices expands reach into APAC with Preclina partnership<\/h1>\/ in E-News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\n

TransCure bioServices, a humanized mouse model CRO, has partnered with Preclina, a South Korean preclinical CRO specializing in autoimmune and inflammatory diseases. The partnership significantly expands TransCure\u2019s reach into the APAC region, while also bolstering its service offerings to further enhance the quality of its research results.<\/h3>\n

<\/p>\n

Biotechnology and pharmaceutical companies in the APAC region will now have better access to a selection of the most advanced mouse models, as well as the full suite of services required for optimized preclinical development \u2013 capabilities that have been challenging to access in the region until now.<\/p>\n

Drug developers in APAC have typically faced many challenges when it comes to preclinical development, from limited access to animal model providers and poor service offering breadth and capacity, to a scarcity of comprehensive, one-stop-shop preclinical partners. What\u2019s more, mouse model providers in the region may not have the standardized, wellrecognized model sets used in international research, making results comparison difficult.<\/p>\n<\/div><\/section>
\n

\"\"<\/div><\/div><\/div>
\n

The partnership between TransCure bioServices and Preclina directly addresses these challenges, providing APAC customers with the full suite of advanced preclinical services under one umbrella, as well as the most advanced, internationally recognized mouse models and cell lines to help optimize and streamline their preclinical programmes.<\/p>\n

\u201cTransCure\u2019s one-stop-shop offering spans three platforms, more than 50 proven animal models, and a vast selection of technical services,\u201d said Kiave Ho Wang Yin, PhD, Chief Business Officer at TransCure bioServices. \u201cBy joining forces with Preclina, we further bolster those offerings with extensive autoimmune and inflammatory disease expertise, unlocking new insights for APAC-based developers, while bringing our renowned partnership-rather-than-supplier approach to the region. With this foothold, we\u2019re uniquely positioned to grow our capacity in the region and further innovate for the benefit of our sponsors.\u201d<\/p>\n

Preclina is renowned for its highly specialized services in autoimmune and inflammatory disorders, such as NASH, fibrosis, arthritis, and scleroderma. It boasts extensive knowledge in immunology, with expertise in patient-derived cells and animal models that faithfully recapitulate these disorders. Their fully integrated drug discovery platform has made them an indispensable partner for APAC clients developing novel drugs and diagnostic and treatment technologies.<\/p>\n<\/div><\/section>
\n